A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.-Reference-Cited by-同舟云学术

A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:TPS2624-TPS2624
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Burris Howard A.¹,Brose Marcia S.²,Shaw Alice Tsang³,Bauer Todd Michael⁴,Farago Anna F.⁵,Doebele Robert Charles⁶,Smith Steven⁷,Fernandes Michele⁷,Cruickshank Scott⁷,Low Jennifer A.⁷

Affiliation:

1. Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN

2. Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

3. Massachusetts General Hospital Cancer Center, Boston, MA

4. Sarah Cannon Research Institute / Tennessee Oncology, PLLC., Nashville, TN

5. Massachusetts General Hospital, Boston, MA

6. University of Colorado Anschutz Med Campus, Aurora, CO

7. Loxo Oncology, San Francisco, CA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.tps2624

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers;Expert Opinion on Investigational Drugs;2021-03-24

2. From Cancer to Pain Target by Automated Selectivity Inversion of a Clinical Candidate;Journal of Medicinal Chemistry;2018-05-10

3. Larotrectinib (LOXO-101);Recent Results in Cancer Research;2018

4. New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions;Laboratory Investigation;2017-10-31

5. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence;Medical Oncology;2017-04-25